Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.71 USD
+0.03 (3.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.71 0.00 (0.55%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Income Statements
Fiscal Year end for Aptevo Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 3 | 12 | 4 | 32 |
Cost Of Goods | 0 | 0 | 0 | 0 | 20 |
Gross Profit | 0 | 3 | 12 | 4 | 13 |
Selling & Adminstrative & Depr. & Amort Expenses | 29 | 32 | 34 | 32 | 55 |
Income After Depreciation & Amortization | -29 | -29 | -21 | -27 | -43 |
Non-Operating Income | 10 | 36 | -8 | -3 | -2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -19 | 7 | -29 | -31 | -45 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | 7 | -29 | -31 | -45 |
Extras & Discontinued Operations | 1 | 1 | 1 | 13 | 4 |
Net Income (GAAP) | -17 | 8 | -28 | -18 | -40 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -28 | -20 | -26 | -43 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -29 | -29 | -21 | -27 | -43 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.28 | 0.12 | 0.11 | NA | 0.07 |
Diluted EPS Before Non-Recurring Items | -66.96 | -260.79 | -276.21 | NA | -672.69 |
Diluted Net EPS (GAAP) | -62.56 | 69.16 | -267.40 | -230.40 | -610.82 |
Fiscal Year end for Aptevo Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 6.38 | 6.56 | 8.18 | 7.76 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.38 | -6.56 | -8.18 | -7.76 |
Non-Operating Income | NA | 0.19 | 0.23 | 0.23 | 9.58 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -6.20 | -6.33 | -7.95 | 1.83 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -6.20 | -6.33 | -7.95 | 1.83 |
Extras & Discontinued Operations | NA | 0.29 | 0.00 | 0.00 | 0.95 |
Net Income (GAAP) | NA | -5.90 | -6.33 | -7.95 | 2.77 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 0.29 | 0.15 | 0.16 |
Diluted EPS Before Non-Recurring Items | NA | NA | -22.03 | -54.19 | 11.45 |
Diluted Net EPS (GAAP) | NA | -3.52 | -22.03 | -54.19 | 17.18 |